Table 3.
Univariate and multivariate analysis of factors associated with liver dysfunction
| Parameter | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Model 1a | Model 2b | |||||
| HR (95% CI) | p value | HR (95% CI) | p value | HR(95% CI) | p value | |
| IL6 (> 6.53 pg/mL) | 3.1 (1.4–6.6) | 0.003 | 2.67 (1.21–5.94) | 0.016 | 2.5 (1.1–5.4) | 0.024 |
| IL8 (> 60.8 pg/mL) | 1.5 (0.75–3) | 0.25 | ||||
| Sex (Male vs. Female) | 0.66 (0.2–2.2) | 0.49 | ||||
| Age (≥ 65 vs. < 65 years) | 0.99 (0.5–2) | 0.97 | ||||
| ECOG (1 vs. 0) | 0.84 (0.38–1.9) | 0.68 | ||||
| Cirrhosis (Yes vs. No) | 2 (0.62–6.6) | 0.25 | ||||
| Hepatitis B Etiology (Yes vs. No) | 1.3 (0.17–9.3) | 0.82 | ||||
| Hepatitis C Etiology (Yes vs. No) | 1.9 (0.88–3.9) | 0.1 | ||||
| Alcohol Etiology (Yes vs. No) | 1.1 (0.54–2.2) | 0.82 | ||||
| Previous TACE (Yes vs. No) | 1.6 (0.73–3.3) | 0.25 | ||||
| PVI (Yes vs. No) | 1.4 (0.68–2.9) | 0.37 | ||||
| Child–Pugh (B vs. A) | 3.3 (0.98–11) | 0.053 | ||||
| BCLC (C vs. B) | 1.1 (0.53–2.3) | 0.78 | ||||
| Albumin (< 36 g/L) | 3.0 (1.4–6.3) | 0.003 | 1.41 (0.61–3.23) | 0.421 | – | – |
| Total bilirubin (≥ 17 µmol/L) | 4.4 (2.2–9) | < 0.001 | 3.73 (1.72–8.06) | < 0.001 | – | – |
| AFP (≥ 400 vs < 400 ng/mL) | 1.6 (0.73–3.4) | 0.25 | ||||
| Diffuse disease (≥ 10 lesions) | 0.68 (0.34–1.3) | 0.27 | ||||
| Extrahepatic disease | 1.1 (0.53–2.5) | 0.74 | ||||
| mALBI grade (2b and 3 vs. 1 and 2a) | 3.9 (1.9–8.1) | < 0.001 | – | – | 3.1 (1.5–6.5) | 0.003 |
Bold type indicates statistical significance;
IL, interleukin; ECOG, Eastern Cooperative Oncology Group; TACE, transarterial chemoembolization; PVI, Portal vein invasion; BCLC, Barcelona Clinic Liver Cancer; AFP, alfa fetoprotein; mALBI, modified albumin–bilirubin
aModel 1 was identified using Cox regression with albumin and total bilirubin, excluding mALBI grade
bModel 2 was identified using Cox regression with mALBI grade as a composite factor, excluding albumin and total bilirubin